BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial and operating results for the quarter ended September 30, 2011 (Q3 2011). Highlights since the Company’s last quarterly report included:
